20:15 , Aug 11, 2017 |  BC Week In Review  |  Clinical News

Avelas starts Phase II of imaging agent AVB-620 in patients with primary breast cancer

Avelas Biosciences Inc. (La Jolla, Calif.) began a Phase II trial to evaluate a single dose of IV AVB-620 administered prior to surgery to detect malignant tissue in about 100 women with primary, non-recurrent, non-metastatic...
23:33 , May 5, 2017 |  BC Extra  |  Company News

Management tracks

Swedish Orphan Biovitrum AB (SSE:SOBI) named Guido Oelkers president and CEO, effective May 22. He will replace Geoffrey McDonough. Oelkers was CEO at BSN medical GmbH, which Svenska Cellulosa AB SCA (SSE:SCAB) acquired. Regulus Therapeutics...
00:38 , Apr 28, 2017 |  BC Innovations  |  Finance

Hatching VC incubators

While more VCs have created venture incubators to nurture early concepts into full-fledged start-ups, they are aligned more on the need to incubate than on how best to do it. Indeed, a collection of VCs...
00:41 , Feb 3, 2017 |  BC Week In Review  |  Clinical News

AVB-620: Ph Ib data

Data from about 15 patients with primary, non-recurrent breast cancer undergoing surgery in an open-label, dose-escalation, U.S. Phase Ib trial showed that a single dose of IV AVB-620 administered prior to surgery led to no...
07:00 , Aug 22, 2016 |  BC Week In Review  |  Financial News

Avelas Biosciences completes venture financing

Avelas Biosciences Inc. , La Jolla, Calif.   Business: Cancer, Diagnostic   Date completed: 2016-08-18   Type: Venture financing   Raised: $20 million   Investors: Pharmstandard International S.A.; Ervington Investments; Alexandria Venture Investments; Avalon Ventures;...
07:00 , Aug 18, 2016 |  BC Extra  |  Financial News

Avelas' series C round brings in $20M

Avelas Biosciences Inc. (La Jolla, Calif.) raised $20 million in a series C financing led by the Pharmstandard International S.A. subsidiary of Pharmstandard OJSC (RTS:PHST; LSE:PHST). New investors Ervington Investments and Alexandria Venture Investments participated,...
08:00 , Nov 16, 2015 |  BC Week In Review  |  Clinical News

AVB-620: Phase I started

Avelas began an open-label, dose-escalation, U.S. Phase I trial to evaluate single doses of IV AVB-620 in up to 39 patients with stage I-III breast cancer prior to surgery. Avelas Biosciences Inc. , La Jolla,...
07:00 , Sep 15, 2014 |  BC Week In Review  |  Financial News

Avelas Biosciences financial update

Avelas Biosciences Inc. , San Diego, Calif.   Business: Cancer, Diagnostic   Date announced: 2014-09-10   Note: Avelas raised $550,000 in the second tranche of a series B round, bringing the total raised in the...
08:00 , Jan 13, 2014 |  BC Week In Review  |  Company News

Avelas Biosciences board of directors update

Avelas Biosciences Inc. , San Diego, Calif.   Business: Cancer, Diagnostic   Appointed: Jay Lichter, managing director at Avalon Ventures, as chairman; and Nikolay Savchuk, managing director at Torrey Pines Investment  ...
08:00 , Jan 13, 2014 |  BC Week In Review  |  Financial News

Avelas Biosciences completes venture financing

Avelas Biosciences Inc. , San Diego, Calif.   Business: Cancer, Diagnostic   Date completed: 1/9/14   Type: Venture financing   Raised: $6.9 million   Investors: Avalon Ventures; Torrey Pines Investment; WuXi AppTec; private investor  ...